Search Videos and More
News
Dana-Farber Research News 9.15.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 16 through August 31.
News
High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer
SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial of vitamin D combined with standard chemotherapy plus bevacizumab in patients with previously untreated metastatic colorectal cancer.
News
Breast Cancer Research: New Studies Show How Post-Treatment Lifestyle Choices Shape Long-Term Outcomes After Diagnosis
Three studies led by Dana-Farber Cancer Institute researchers have encouraging implications for patients with breast cancer.
News
Long-term Metastatic Melanoma Survival Dramatically Improves on Immunotherapy
Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report from Dana-Farber Cancer Center and Weill Cornell Medicine investigators and their colleagues.
News
Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer
Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor – Results of the Phase 3 TiNivo-2 Study
News
Antibody-Drug Conjugate Found Effective Against Brain Metastases in Patients with HER2-Positive Breast Cancer
A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer.
Symposium
ESMO Congress 2024
Learn more about prostate, bladder and kidney cancer studies led by Dana-Farber presented at ESMO Congress 2024.
News
Comprehensive Cancer Research from Dana-Farber Leads ESMO Congress 2024
Innovations in breast cancer, targeted therapies, antibody drug conjugates, and kidney cancer
News
Ann Partridge Receives 2024 ESMO Award for Significant Contributions to Breast Cancer Research and Patient Care
The European Society for Medical Oncology (ESMO) recognized Ann Partridge, MD, MPH, of Dana-Farber Cancer Institute, as a recipient of the 2024 ESMO Award: Addressing the Unintended Consequences of Cancer Care.
News
Adolescent Glioma Subtype Responds to CDK4/6 Inhibitor
CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new research from Dana-Farber Cancer Institute and the Institute of Cancer Research in London.
News
Dana-Farber President and CEO Laurie Glimcher, MD, Announces Her Plans to Step Down Capping a Highly Successful Tenure Marked with Discovery and Innovation
Acclaimed medical oncologist and researcher Benjamin Ebert, MD, PhD, appointed to lead the world-renowned cancer center
News
Dana-Farber Research News 9.01.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 1 through August 15.